FDANews; August 30, 2021 – Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation.

GenomeWeb; August 27, 2021 – CellMax Life said this week that its FirstSight colorectal precancer and cancer detection blood test has received Breakthrough Device Designation from the US Food and Drug Administration.

Aug. 26, 2021 – The FirstSight blood test is a liquid biopsy, which will help measure colorectal neoplasia associated epithelial cells and DNA markers in human blood

January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.

MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had advanced adenomas, an investigator said.

OncLive | May 08, 2020 The multimodal FirstSight^CRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (CRC), explained Shai Friedland, MD, who added that the noninvasive assay could lead to improved screening compliance.